Table 3 Clinicopathological features, tumor markers, and patient survival (univariate analysis)
From: Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells
Variable | 5-Year DFS HR (95 % CI) | P-value | 5-Year OS HR (95 % CI) | P-value |
|---|---|---|---|---|
A. univariate analysis | ||||
Age (≥55 years vs <55 years) | 0.77(0.43-1.36) | 0.3659 | 0.76(0.38-1.51) | 0.4313 |
Pathology (serous vs other) | 0.51(0.24-1.09) | 0.0833 | 0.69(0.29-1.67) | 0.4100 |
Histological grade (poor vs well/moderate) | 0.61(0.34-1.07) | 0.0859 | 0.73(0.37-1.43) | 0.3587 |
FIGO stage (III/IV vs I/II) | 5.95(1.44-24.55) | 0.0137 | 8.41(1.14-62.03) | 0.0368 |
Malignant cells in ascites (yes vs no) | 1.96(1.09-3.51) | 0.0242 | 1.59(0.79-3.20) | 0.1913 |
Lymph node metastasis (yes vs no) | 3.29(1.99-6.03) | 0.0001 | 2.55(1.28-5.07) | 0.0076 |
Liver or lung metastasis (yes vs no) | 4.28(2.35-7.80) | <0.001 | 3.62(1.81-7.25) | 0.0003 |
Residual tumor (>1 vs <1) | 2.04(1.14-3.66) | 0.0164 | 1.81(0.90-3.63) | 0.0950 |
TLR4 (high vs low) | 1.78(0.79-4.02) | 0.1657 | 1.68(0.67-4.19) | 0.2685 |
MyD88 (positive vs negative) | 0.10(0.02-0.41) | 0.0014 | 0.09(0.01-0.67) | 0.0185 |
B. multivariate analysis | ||||
FIGO stage (III/IV vs I/II) | 4.57(1.04-20.17) | 0.0446 | 7.89(1.03-58.90) | 0.0468 |
Malignant cells in ascites (yes vs no) | 1.38(0.73-2.60) | 0.3255 | —— | —— |
Lymph node metastasis (yes vs no) | 1.25(0.62-2.52) | 0.5315 | 0.94(0.43-2.05) | 0.8713 |
Liver or lung metastasis (yes vs no) | 2.21(1.05-4.69) | 0.0380 | 2.47(1.13-5.41) | 0.0237 |
Residual tumor (>1 vs <1) | 1.04(0.54-1.99) | 0.9082 | —— | —— |
MyD88 (high vs low) | 0.11(0.23-0.47) | 0.0027 | 0.12(0.02-0.89) | 0.0382 |